|Shares Out. (in M):||51||P/E||0.0x||0.0x|
|Market Cap (in $M):||210||P/FCF||0.0x||0.0x|
|Net Debt (in $M):||-170||EBIT||0||0|
I believe QLTI warrants examination because:
By the end of this year, QLTI should have $3.20/share in net cash. They also have contingent payments they should receive (related to their sale of Visudyne) whose present value is ~$0.20 per share.
Given the slowness of partnering discussions and AUXL’s reluctance to develop the drug, as mentioned in AUXL's QLTI conf call, let’s conservatively assume this drug is worthless.
So what is QLTI’s tax inversion candidacy worth?
Tax inversion requires QLTI own at least 20% of the pro-forma company.
Given that a company with a market cap of more than $2 billion probably would not pay the QLTI premium to meet this rule, I screened for pharma/biotech or similar companies with US tax domiciles and market caps and enterprise values of $2 billion and below.
I looked for those that would have the largest savings relative to the premium they would have to pay and derived the following lists of potential buyers:
Potential biotech/pharma/med-tech buyers:
Potential other buyers:
I estimated the present value of tax savings, net of tax assets, of $200MM to $900MM for the first 5 buyers above.
AUXL was willing to pay an EV of ~$175MM for such savings.
US Congress changes tax inversion law.